Skip to main content
Advertisement
  • Other Publications
    • EMBO Press
    • EMBO Molecular Medicine (Home)
    • The EMBO Journal
    • EMBO reports
    • Molecular Systems Biology
    • Life Science Alliance
Login

   

Search

Advanced Search

Journal

  • Home
  • Latest Online
  • Current Issue
  • Archive
  • Article Collections
  • Subject Collections

Authors & Referees

  • Submit
  • Author Guidelines
  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Referee Guidelines
  • Bibliometrics
  • Open Access

Info

  • E-Mail Editorial Office
  • Alerts
  • RSS Feeds
  • Reprints & Permissions
  • Advertise & Sponsor
  • Media Partners
  • News & Press
  • Customer Service
  • Home
  • EMBO Molecular Medicine: 10 (11)

Open Access

News & Views

Cancer immunotherapy in routine cost‐effective cancer care?

View ORCID ProfileSir Marc Feldmann
DOI 10.15252/emmm.201809660 | Published online 15.10.2018
EMBO Molecular Medicine (2018) 10, e9660
Sir Marc Feldmann
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Sir Marc Feldmann (marc.feldmann{at}kennedy.ox.ac.uk)1
  1. 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
View Abstract
  • Article
  • Transparent Process
Loading

Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al, 2018).

See also: Pfeiffer et al (November 2018)

EMBO Mol Med (2018) 10: e9660OpenUrlAbstract/FREE Full Text

The existence of immune responses to human cancer is nowadays well established (reviewed in Miller & Sadelain, 2015), and immunotherapy has become an increasingly important part of cancer medical care. The first real therapeutic success of immunotherapy in cancer was the use of antibodies targeted to cancer cells, which harnessed the immune response to help deliver their therapeutic effect, such as rituximab (anti‐CD20) based on Fc engagement (Mellor et al, 2013), or trastuzumab (anti‐HER2) (Carter et al, 1992) based on FcR (and possibly other mechanisms). For many however, “cancer immunotherapy” evokes “checkpoint inhibitors”, i.e., antibodies to inhibitory molecules. Successful clinical examples are CTLA‐4 (Leach et al, 1996), PD‐1 and PD‐L1 (Topalian et al, 2012), but other candidates are currently in clinical development. The response is unfortunately not universal, with ~20% of patients exhibiting good responses in susceptible cancers. Moreover, “unleashing” the immune response comes at a price, i.e., autoimmunity and inflammation in many patients, which can at times be life‐threatening and expensive to treat.

Twenty‐five years ago, Zelig Eshhar and his colleagues engineered and expressed chimeric antigen receptors (CAR) constituted of the single Fv chain of the antibody molecule combined with the constant region of the T‐cell receptor, in order to kill tumour cells (Eshhar et al, 1993). This pioneering work has been optimized and amplified, and brought to experimental and clinical fruition by several groups (reviewed in Miller & Sadelain, 2015).

For B‐cell tumours expressing CD19, the success of CAR‐T cells has been truly remarkable, and suggests that many more cancers will be treatable, or even curable. However, generating these cells in the scale needed has been a technical feat, to which many companies contributed, and the first product was put on the market, initially at $495,000. This initial success is expected to move on to many other target cancer antigens, and to many patients who require treatment, raising the issue of the financial burden for patients/healthcare systems.

Might there be cheaper alternatives? Yes, the knowledge gained from the clinical success of CAR‐T cells has enabled others to try to simplify and mimic the process, without the costly patient‐specific therapy or extra‐corporeal engineering. The approach reported in this issue of EMBO Molecular Medicine (Pfeiffer et al, 2018) involves the generation of anti‐viral vectors that target CD8 T cells and can lead to the generation of CAR‐T cells in vivo. The reprogramming of human cytotoxic T cells has been achieved using vectors reported recently, which can selectively deliver genes into CD8 T cells (Zhou et al, 2015; Bender et al, 2016). Injecting these vectors once into “humanized” mice was able to generate CD19‐specific CAR‐T cells in 7 out of 10 mice. These CAR‐T cells successfully depleted human B cells. The “authenticity” of these cells is supported by the fact that three mice developed high levels of human cytokines and symptoms reminiscent of cytokine release syndrome, a well‐known problem in CAR‐T cell therapy that can be dealt with by using anti‐cytokine antibodies.

In the early days of monoclonal antibodies, the immunogenicity of murine monoclonal antibodies was envisaged as a major hurdle, leading to failure of the inventors' institution to patent the process. This hurdle was overcome in large part by appropriate genetic and molecular engineering, facilitating the success of immunotherapy to cytokines and cancers. In the present study, the benefit of combining basic research to improve the understanding of key molecules such as TcR, together with antibodies and genetic engineering skills to yield variants to a new clinically successful therapy, is clearly demonstrated. It will take considerable time and effort for the simplified process reported by Pfeiffer et al (2018) to be developed and able to reach patients, but it constitutes the first step towards converting CAR‐T cell therapy from an autologous, individualized to an off‐the‐shelf product, not only restricted to a lucky few.

Conflict of interest

M. F. is a consultant to Celgene, Inc.

References

  1. ↵
    Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Pluckthun A, Maisner A, Bucholz CJ (2016) Receptor‐targeted nipah virus glycoproteins improve cell‐type selective gene delivery and reveal a preference for membrane‐proximal cell attachment. PLoS Pathog 12: e1005641
    OpenUrlCrossRef
  2. ↵
    Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver M, Shepard M (1992) Humanization of an anti‐p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody‐binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 90: 720–724
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Leach DR, Krummel MF, Allison JP (1996) Enhancement of anti‐tumor immunity by CTLA‐4 blockade. Science 271: 1734–1736
    OpenUrlAbstract
  5. ↵
    Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A (2013) A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6: 1
    OpenUrlCrossRefPubMed
  6. ↵
    Miller JFAP, Sadelain M (2015) The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27: 439–449
    OpenUrlCrossRefPubMed
  7. ↵
    Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RB, Danisch S, Costa C, Wels WS, Modlich U, Stripecke R et al (2018) In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome. EMBO Mol Med 10: e9158
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med 366: 2443–2454
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Zhou Q, Uhlig KM, Muth A, Kimpel J, Levy C, Munch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C et al (2015) Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4‐targeted lentiviral vectors. J Immunol 195: 2493–2501
    OpenUrlAbstract/FREE Full Text

This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

  • © 2018 The Author. Published under the terms of the CC BY 4.0 license
View Abstract
Previous Article in this IssueNext Article in this Issue
Back to top

  • PDF
  • Share
  • Export
  • Print
Loading

PDF

In this Issue
Volume 10, Issue 11
01 November 2018
EMBO Molecular Medicine: 10 (11)
About the cover
Alert me when this article is cited
Alert me if a correction is posted

Article

  • Article
    • Conflict of interest
    • References
  • Transparent Process

Related Content

More News & Views

  • I BET on anti‐FGFR to fight cancer resistance
    Rosaria Benedetti, Lucia Altucci
    EMBO Molecular Medicine 11: e10116
  • Split otoferlins reunited
    Jeffrey R Holt, Gwenaelle SG Geleoc
    EMBO Molecular Medicine 11: e9995
  • How much does a disrupted mitochondrial network influence neuronal dysfunction?
    Zofia MA Chrzanowska‐Lightowlers, Robert N Lightowlers
    EMBO Molecular Medicine 11: e9899
More News & Views

Related Articles

Cited By...

Request Permissions

Subject Areas

  • Cancer
  • Immunology

Journal

  • Latest Online
  • Current Issue
  • Archive
  • Focus Pages
  • Bibliometrics
  • E-Mail Editorial Office
  • Privacy Policy

Authors & References

  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Author Guidelines
  • Referee Guidelines
  • Open Access
  • Submit

Info

  • Alerts
  • RSS Feeds
  • Reprints & Permissions
  • Advertise & Sponsor
  • News & Press
  • Customer Service

EMBO

  • Funding & Awards
  • Events
  • Science Policy
  • Members
  • About EMBO

Online ISSN  1757-4684

Copyright© 2019 EMBO

This website is best viewed using the latest versions of all modern web browsers. Older browsers may not display correctly.